Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

Abstract excerpt

BACKGROUND: Panel sequencing, whole-exome sequencing (WES) and whole-genome sequencing (WGS) often uncover therapeutic targets for cancer patients. However, it is still largely unclear to what extent patients directly benefit from broader analyses over panel sequencing alone. MATERIALS AND METHODS: We analyzed the molecular findings and recommendations issued by our molecular tumor board (MTB) in a cohort of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Genomics and Rare Diseases
• Share to Lung Cancer Treatments and Mutations